Correlation of Genogroup I, Genotype 1 (GI.1) Norovirus Neutralizing Antibody Levels With GI.1 Histo-Blood Group Antigen–Blocking Antibody Levels
The Journal of Infectious Diseases · 16.12.2024 · 230 (6) · 1376-1379
DOI: 10.1093/infdis/jiae311 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift The Journal of Infectious Diseases, online erschienen am 12.06.2024. Verfasst von Robert L Atmar und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Baylor College of Medicine, Houston, Texas, USA. Hauptthemen laut MEDLINE: Antibodies, Neutralizing, Antibodies, Viral, Blood Group Antigens, Caliciviridae Infections. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 15 Literaturangaben. Gefördert von: Takeda Vaccines Business Unit.
Abstract (Originalsprache)
Background
The in vitro cultivation of human noroviruses allows a comparison of antibody levels measured in neutralization and histo-blood group antigen (HBGA)–blocking assays.
Methods
Serum samples collected during the evaluation of an investigational norovirus vaccine (HIL-214 [formerly TAK-214]) were assayed for neutralizing antibody levels against the vaccine's prototype Norwalk virus/genogroup I, genotype 1 (GI.1) (P1) virus strain. Results were compared with those previously determined using HBGA-blocking assays.
Results
Neutralizing antibody seroresponses were observed in 83% of 24 vaccinated adults, and antibody levels were highly correlated (r = 0.81; P < .001) with those measured by HBGA blocking.
Conclusions
Genogroup I, genotype 1 (GI.1)–specific HBGA-blocking antibodies are a surrogate for neutralization of GI.1 norovirus. Clinical Trials Registration. Clinicaltrials.gov NCT02475278
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.
- Department of Molecular Virology & Microbiology, Baylor College of Medicine, Houston, Texas, USA.
- Icosavax, Seattle, Washington, USA.
- Takeda Pharmaceuticals International, Zurich, Switzerland (former affiliation).
ORCID-Profile: Robert L Atmar, Khalil Ettayebi, Sasirekha Ramani, Mary K Estes
Förderung
- Takeda Vaccines Business Unit
Zitieren
APA
Atmar, R. L., Ettayebi, K., Neill, F. H., Braun, R. P., Sherwood, J., Ramani, S., & Estes, M. K. (2024). Correlation of Genogroup I, Genotype 1 (GI.1) Norovirus Neutralizing Antibody Levels With GI.1 Histo-Blood Group Antigen–Blocking Antibody Levels. The Journal of Infectious Diseases, 230(6), 1376-1379. https://doi.org/10.1093/infdis/jiae311
Vancouver
Atmar RL, Ettayebi K, Neill FH, Braun RP, Sherwood J, Ramani S, et al. Correlation of Genogroup I, Genotype 1 (GI.1) Norovirus Neutralizing Antibody Levels With GI.1 Histo-Blood Group Antigen–Blocking Antibody Levels. The Journal of Infectious Diseases. 2024;230(6):1376-1379. doi:10.1093/infdis/jiae311
BibTeX
@article{Atmar2024,
author = {Atmar, Robert L and Ettayebi, Khalil and Neill, Frederick H and Braun, Ralph P and Sherwood, James and Ramani, Sasirekha and Estes, Mary K},
title = {Correlation of Genogroup I, Genotype 1 (GI.1) Norovirus Neutralizing Antibody Levels With GI.1 Histo-Blood Group Antigen–Blocking Antibody Levels},
journal = {The Journal of Infectious Diseases},
year = {2024},
volume = {230},
number = {6},
pages = {1376--1379},
doi = {10.1093/infdis/jiae311}
}
EUVIMED